Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy Participants
Sponsor: Vertex Pharmaceuticals Incorporated
Summary
The purpose of the study is to evaluate the pharmacokinetics (PK) of Suzetrigine (SUZ) and its metabolite in the absence and presence of efavirenz, a moderate CYP3A inducer. In addition, the purpose is to evaluate the safety and tolerability of SUZ when administered in the absence and presence of efavirenz.
Official title: A Phase 1, Open-label Drug-drug Interaction Study to Evaluate the Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy Subjects
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
18
Start Date
2026-05-07
Completion Date
2026-07-11
Last Updated
2026-05-06
Healthy Volunteers
Yes
Conditions
Interventions
Suzetrigine
Tablet for oral administration.
Efavirenz
Tablet for oral administration.